CurrentUnitedHealthcarePolicy CS098ID.B

Sleep Studies (for Idaho Only)

Medically necessary coverage criteria and definitions for home and attended sleep studies, daytime sleep tests, PAP titration, repeat testing, and excluded/experimental studies for members in Idaho (including Idaho Medicaid Plus). Provides applicable CPT/HCPCS codes and clinical definitions.

Policy Summary

PayerUnitedHealthcare

PolicySleep Studies (for Idaho Only)

Policy CodePolicy CS098ID.B

Change TypeDocumentation requirement addedarchival of prior version

Effective DateApr 1, 2026

Next Review Date

Key ActionDocument relevant medical history, physical examination, and results of pertinent diagnostic tests that fully support medical necessity and make records available upon request.

SourceLink

POLICY UPDATE CHANGES

Added language that the patient's medical record must contain documentation that fully supports the medical necessity for the requested services

Removed reference link to the guidelines titled 'Medical Records Documentation Used for Reviews'

Archived previous policy version CS098ID.A

HSAT adultsCovered Indications

PSG <18Covered Indication

ActigraphyNot Medically Necessary

PAP-NapNot Medically Necessary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

1Material documentation change(s)

≥15/hrVA/DoD HSAT threshold

Coverage Summary

This policy (Policy CS098ID.B, effective April 1, 2026) provides coverage criteria for diagnostic sleep testing in Idaho. Coverage stance is mixed: HSAT (unattended home sleep apnea testing) is medically necessary for adults with suspected obstructive sleep apnea (OSA), while attended full‑channel polysomnography (PSG) is required/medically necessary for children and for adults with specified comorbidities or when HSAT results are negative, indeterminate, or technically inadequate. Not covered (not medically necessary) items include actigraphy for diagnosis of sleep disorders and PAP‑Nap/abbreviated daytime sleep studies. The policy requires that the patient medical record contain documentation that fully supports medical necessity (relevant history, physical exam, and pertinent test results) and that such documentation be made available upon request.

Key thresholds

HSAT adequate monitoring timeMinimum of 4 hours recording time

Apnea (definition)≥ 90% decrease in apnea sensor excursions vs baseline for ≥ 10 seconds

Hypopnea (definition)≥ 30% reduction in airflow for ≥ 10 seconds with ≥ 3% oxygen desaturation or associated arousal

OSA severity - MildAHI or RDI ≥ 5 and < 15 events/hour

OSA severity - ModerateAHI or RDI ≥ 15 and ≤ 30 events/hour

OSA severity - SevereAHI or RDI > 30 events/hour

FEV1% cutoff for PSG considerationFEV1% predicted < 60

BMI cutoff for PSG considerationBMI > 50

VA/DoD HSAT diagnostic thresholdREI or AHI ≥ 15 events/hour to establish moderate to severe OSA

Obesity hypoventilation diagnostic PaCO2Arterial PaCO2 ≥ 45 mmHg (with BMI ≥ 30)

Medical-Necessity Criteria

Home Sleep Apnea Testing (HSAT) - Medical Necessity

HSAT is medically necessary for evaluating adults with suspected OSA:

HSAT is medically necessary for evaluating adults with suspected Obstructive Sleep Apnea (OSA)

Adequate HSAT = minimum 4 hours and includes nasal pressure, chest and abdominal respiratory inductance plethysmography, and oximetry.

Attended Full-Channel Polysomnography (PSG) - Medical Necessity

Attended PSG is medically necessary for evaluating individuals with suspected OSA when ANY of the following are met:

Results of previous HSAT are negative, indeterminate, or technically inadequate to make a diagnosis of OSA

Individual is a child or adolescent (i.e., less than 18 years of age)

Known comorbid medical conditions that prohibit HSAT (ONE of)

Coding

Referenced CPT codesCPT

95782	Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, attended by a technologist.
95783	Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bi-level ventilation, attended by a technologist.
95800	Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (e.g., by airflow or peripheral arterial tone), and sleep time.
95801	Sleep study, unattended, simultaneous recording; minimum of heart rate, oxygen saturation, and respiratory analysis (e.g., by airflow or peripheral arterial tone).
95803	Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording).
95805	Multiple sleep latency or maintenance of wakefulness testing, recording, analysis and interpretation of physiological measurements of sleep during multiple trials to assess sleepiness.
95806	Sleep study, unattended, simultaneous recording of, heart rate, oxygen saturation, respiratory airflow, and respiratory effort (e.g., thoracoabdominal movement).
95807	Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended by a technologist.
95808	Polysomnography; any age, sleep staging with 1-3 additional parameters of sleep, attended by a technologist.
95810	Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist.

1–10 of 11

1/2

Referenced HCPCS/G codesHCPCS

G0398	Home sleep test (HST) with type III portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ECG/heart rate and 1 oxygen saturation.
G0400	Home sleep test (HST) with type IV portable monitor, unattended; minimum of 3 channels

FDA device product codes referencedmixed

OLV	Product code for systems to record and analyze PSG information (FDA 510(k))
MNR	Product code for HSAT devices (FDA 510(k))

Provider Actions & Authorization

Documentation Required

Support medical necessity in record

Document relevant medical history, physical examination findings, and results of pertinent diagnostic tests or procedures that fully support the medical necessity for the requested sleep study or service. Examples include history, physical exam, and diagnostic test results. Records must be legible, maintained in the patient's medical record, and made available upon request.

Relevant medical history
Physical examination findings
Results of pertinent diagnostic tests or procedures
Records must be available upon request

Prior Authorization

Policy applies to Idaho members

This medical policy applies only to the state of Idaho, including Idaho Medicaid Plus plans. Providers must follow Idaho-specific prior authorization and coverage processes when requesting services covered by this policy.

Background & Evidence

Background: HSAT and PSG are distinct diagnostic approaches. HSAT refers to unattended portable monitoring that does not determine sleep stage and must include a minimum of 4 hours of adequate recording with sensors such as nasal pressure, chest and abdominal respiratory inductance plethysmography, and oximetry. PSG (polysomnography) is an attended, laboratory‑based study using multiple channels to record brain activity, eye movements, breathing, oxygenation and other physiological signals. Device classifications (AASM/Collop) group systems as Type 1 (full attended PSG ≥7 channels), Type 2 (full unattended PSG ≥7 channels), Type 3 (limited channel devices, ~4–7 channels) and Type 4 (1–2 channels, often oximetry). Rationale for home versus in‑lab testing includes similar diagnostic and outcome performance in selected, uncomplicated patients with high pretest probability of OSA, lower resource use for HSAT, but greater need for PSG when comorbid cardiorespiratory disease or other conditions exist or when HSAT is non‑diagnostic. Diagnostic thresholds follow AASM guidance: OSA is confirmed if obstructive events are > 15 events/hour without symptoms or > 5 events/hour with symptoms; severity is mild AHI/RDI ≥5 and <15, moderate ≥15 and ≤30, and severe >30. The policy cites AASM and systematic reviews showing comparable outcomes between home‑based and in‑lab pathways in appropriate patients and documents night‑to‑night variability and limitations of HSAT (single‑night HSAT adequate for many but repeat HSAT not preferred if initial result is negative/inconclusive).

Evidence	Summary
AASM diagnostic threshold guidance
OSA confirmed if obstructive events >15/hour without symptoms or >5/hour with symptoms (AASM diagnostic guidance).
Feasibility of single-night HSAT
Single-night HSAT can correctly diagnose OSA in most high-pretest-probability patients; reported data loss 3%-33%; night-to-night variability comparable to PSG though intraindividual variability exists.
Comparative outcomes
Randomized and observational studies show similar functional outcomes and CPAP adherence for home-based vs in-lab pathways in selected populations.
PAP-Nap comparative results
Pilot and cohort data: PAP-Nap group had higher rates of completing overnight titrations (90% vs 63%), filling PAP prescriptions (85% vs 35%), maintaining regular PAP use (67% vs 23%), and objective adherence 49%-56% vs 12%-17% controls; larger studies needed.
AASM actigraphy recommendations
AASM provides multiple conditional recommendations for actigraphy use in insomnia and circadian disorders and strongly recommends against using actigraphy in place of EMG for PLMD.
HSAT device and monitoring definitions
HSAT is unattended testing with minimum 4 hours recording and defined sensor set; REI is used as surrogate for AHI in HSAT.

Definitions

HSATUnattended diagnostic studies to assess for OSA without sleep staging; adequate HSAT = minimum 4 hours with nasal pressure, chest and abdominal RIP, and oximetry

Revision History

2026-04-01RevisedLatest

Added language that the patient's medical record must contain documentation that fully supports the medical necessity for the requested services; documentation must include relevant medical history, physical exam, and results of pertinent diagnostic tests or procedures, be legible, maintained, and made available upon request.

2026-04-01Removed

Removed reference link to the guidelines titled 'Medical Records Documentation Used for Reviews'.

2026-04-01

Policy Summary

PayerUnitedHealthcare

PolicySleep Studies (for Idaho Only)

Policy CodePolicy CS098ID.B

Change TypeDocumentation requirement addedarchival of prior version

Effective DateApr 1, 2026

Next Review Date

Key ActionDocument relevant medical history, physical examination, and results of pertinent diagnostic tests that fully support medical necessity and make records available upon request.

SourceLink

On This Page

Significant Chronic Pulmonary Disease defined by FEV1% predicted < 60FEV1% predicted < 60
Progressive neuromuscular disease/neurodegenerative disorder (examples: Parkinson's disease, myotonic dystrophy, amyotrophic lateral sclerosis, multiple sclerosis with associated pulmonary disease, history of stroke with persistent neurological sequelae)
Moderate to severe heart failure (NYHA class III or IV) or left ventricular ejection fraction ≤ 40LVEF ≤ 40 or NYHA III/IV
Body mass index (BMI) > 50BMI > 50
Obesity Hypoventilation Syndrome
Documented ongoing epileptic seizures in the presence of symptoms of sleep disorder
Chronic opiate medication use (> 3 months)> 3 months

Attended PSG - Additional Indications

Attended full-channel Polysomnography is medically necessary when clinical assessment suggests any of the following conditions:

Periodic Limb Movement Disorder (PLMD) (not leg movements associated with another disorder such as sleep disordered breathing)

Restless Legs Syndrome (RLS)/Willis-Ekbom Disease that has not responded to treatment

Parasomnia with documented disruptive, violent, or potentially injurious sleep behavior suspicious of REM Sleep Behavior Disorder (RBD)

Narcolepsy, once other causes of Excessive Sleepiness have been ruled out by appropriate clinical assessment

Central Sleep Apnea

To rule out Central Sleep Apnea prior to implantation and/or calibration of an implantable hypoglossal nerve stimulator

Studies Not Medically Necessary

The following are not medically necessary due to insufficient evidence:

Attended full-channel Polysomnography for evaluating Circadian Rhythm Disorders

Attended full-channel Polysomnography for evaluating Depression

Attended full-channel Polysomnography for evaluating Insomnia

Actigraphy for any sleep disorders

Abbreviated daytime sleep studies (e.g., PAP-Nap)

PAP-Nap considered not medically necessary due to insufficient evidence

Daytime Sleep Studies - MSLT and MWT

Medical necessity criteria for daytime tests:

ALL of the following

ALL of the following
- Suspected Narcolepsy or idiopathic Hypersomnia
- Other causes of Excessive Sleepiness have been excluded by appropriate clinical assessment
ANY of the following
- An adult who is unable to stay awake, resulting in a safety issue
- Assessing response to treatment in adults with sleep disorders
MWT is unproven and not medically necessary in children and adolescents < 18 years of age

Attended PAP Titration - Medical Necessity

When attended PSG criteria are met, the following are medically necessary:

A split-night sleep study in a healthcare facility or laboratory for diagnosis and PAP titration

A full night study for PAP titration when a split-night study is inadequate or not feasible and the individual has a confirmed diagnosis of OSA

Attended Repeat Testing - Medical Necessity

Repeat attended PSG and repeat PAP titration are medically necessary when ALL of the following apply:

Individual has persistent or new symptoms despite documented appropriate current treatment or PAP therapy

Problems such as equipment failure, improper mask fit, pressure leaks, unsuccessful titration, inadequate pressure, and medical problems (e.g., nasal congestion) have been addressed and appropriately managed

Follow-up PSG/HSAT recommendations (AASM Caples et al., 2021)

Follow-up PSG or HSAT is recommended/used in the following clinical circumstances:

Reassessment of patients with recurrent or persistent symptoms despite good PAP adherence

Assess response to treatment with non-PAP interventions

Clinically significant weight gain or loss since diagnosis or initiation of treatment

Reassessment of sleep-related hypoxemia and/or sleep-related hypoventilation following initiation of treatment for OSA

Patients being treated for OSA who develop or have a change in cardiovascular disease

Patients with unexplained PAP device-generated data

AASM: MSLT/MWT indications and limitations

MSLT is indicated as part of evaluation to confirm narcolepsy

MSLT may be indicated to help differentiate idiopathic hypersomnia from narcolepsy

MSLT is not routinely indicated in initial evaluation/diagnosis of OSA or assessment after nasal CPAP

MSLT is not routinely indicated for evaluation of sleepiness in medical/neurological disorders (other than narcolepsy), insomnia or circadian rhythm disorders

Repeat MSLT may be indicated when initial test was affected by extraneous circumstances, ambiguous/uninterpretable, or suspected narcolepsy despite prior nonconfirmatory testing

MWT may be indicated to assess response to treatment and to assess ability to remain awake when inability to remain awake poses safety risk

AASM: Use of actigraphy (Smith et al., 2018b)

AASM recommendations (conditional/strong) for actigraphy:

Use actigraphy to estimate sleep parameters in adult patients with insomnia disorder (Conditional)

Use actigraphy in assessment of pediatric patients with insomnia disorder (Conditional)

Use actigraphy in assessment of adult patients with circadian rhythm sleep-wake disorder (Conditional)

Use actigraphy in assessment of pediatric patients with circadian rhythm sleep-wake disorder (Conditional)

Use actigraphy integrated with HSAT devices to estimate total sleep time during recording in adults suspected of sleep-disordered breathing when no alternative objective measurement exists (Conditional)

Use actigraphy to monitor total sleep time prior to MSLT in adults and pediatrics with suspected central disorders of hypersomnolence (Conditional)

Use actigraphy to estimate total sleep time in adults with suspected insufficient sleep syndrome (Conditional)

Do not use actigraphy in place of electromyography for diagnosis of periodic limb movement disorder in adults and pediatric patients (Strong)

Strong recommendation against replacing EMG for PLMD diagnosis

AASM: HSAT vs PSG recommendations (Kapur et al., 2017)

PSG is standard diagnostic test for OSA in adults when concern exists based on comprehensive sleep evaluation

PSG or HSAT with a technically adequate device should be used for diagnosis of OSA in uncomplicated adult patients with increased risk of moderate to severe OSA

If a single HSAT is negative, inconclusive, or technically inadequate, perform PSG for diagnosis of OSA

PSG rather than HSAT should be used for diagnosis of OSA in patients with significant cardiorespiratory disease, potential respiratory muscle weakness due to neuromuscular condition, awake hypoventilation or suspicion of sleep-related hypoventilation, chronic opioid medication use, history of stroke or severe insomnia

Split-night PSG may be used if clinically appropriate rather than full-night PSG (Weak)

When initial PSG is negative and clinical suspicion remains, a second PSG may be considered (Weak)

AASM: Multiple-night HSAT

Evidence insufficient to support routine performance of more than a single night's HSAT

After a single negative, inconclusive, or technically inadequate HSAT result, performance of a PSG is strongly recommended rather than repeating HSAT

VA/DoD: HSAT recommendations (2019)

For patients with high pretest probability for OSA, suggest a manually-scored type III HSAT using event index (RDI, AHI) ≥ 15 events/hour to establish diagnosis of moderate to severe OSARDI or AHI ≥ 15 events/hour

For patients with high pretest probability and a non-diagnostic HSAT (technically inadequate or AHI < 5), recommend repeat HSAT or lab-based PSG testing for OSAAHI < 5 or technically inadequate

PAP-Nap findings and limitations

Evidence summary of PAP‑Nap test utility in insomnia patients with SDB:

PAP-Nap combines mask/pressure desensitization, emotion-focused therapy, mental imagery, and physiological exposure during a 100-minute nap

In a comparative cohort (n=39 nap-tested vs n=60 historical controls), nap-tested group had higher rates of completing overnight titrations (90% vs 63%), filling PAP prescriptions (85% vs 35%), maintaining regular PAP use (67% vs 23%), and higher objective adherence (49%-56% vs 12%-17%)

Further results from large, prospective studies are needed to assess clinical value

Denial Risk

Actigraphy and certain PSG indications not covered

Claims for actigraphy and certain attended PSG indications are considered not medically necessary and may be denied.

Affected CPT codes: 95803 (Actigraphy), 95808 (Polysomnography; any age, attended), 95805 (MSLT/MWT)
Actigraphy for any sleep disorder is not medically necessary
Attended PSG for Circadian Rhythm Disorders, Depression, or Insomnia is not medically necessary
Abbreviated daytime sleep studies (e.g., PAP-Nap) are not medically necessary

Documentation Required

Medical record documentation requirement

The patient's medical record must contain documentation that fully supports the medical necessity for the requested services. Effective April 1, 2026, added language emphasizes that documentation (including relevant medical history, physical exam, and diagnostic test results) will be used in utilization reviews and authorization decisions. Documentation should be legible, maintained in the chart, and made available upon request.

Prior Authorization

Policy modification effective 2026-04-01 requires documentation for reviews

Effective date: April 1, 2026. This policy modification adds required documentation language that will be used during utilization reviews and prior authorization decisions. This is a material change.

Documentation Required

Use clinical judgment for SDB treatment prior to PSG-MSLT testing in pediatrics

For children and adolescents, clinicians should use clinical judgment to determine whether treatment for sleep-disordered breathing is indicated before performing PSG followed by MSLT testing. Consider treating identified SDB prior to proceeding with PSG-MSLT in pediatric patients.

Denial Risk

HSAT negative/inconclusive result handling

If a single HSAT is negative, inconclusive, or technically inadequate and clinical suspicion for OSA remains, in-laboratory PSG is strongly recommended rather than repeating HSAT. Repeating HSAT instead of proceeding to PSG may risk diagnostic failure and could result in denial of the definitive diagnostic pathway.

Diagnostic workflow: single HSAT → if negative/inconclusive and suspicion remains → perform attended in-lab PSG (strong recommendation)

AHI (Apnea Hypopnea Index)Number of apneas plus hypopneas per hour of sleep (events/hour)

REI (Respiratory Event Index)Total respiratory events per hour of monitoring time; used for HSAT as surrogate for AHI

ApneaCessation of airflow (≥90% decrease) lasting ≥10 seconds; classified as obstructive, central, or mixed based on respiratory effort

Hypopnea≥30% reduction in airflow for ≥10 seconds with ≥3% desaturation or associated arousal

PSGPolysomnography: attended in-lab full-channel sleep study; standard diagnostic test for OSA in certain populations

PAP-NapDaytime abbreviated cardio-respiratory nap combining desensitization and psychological interventions during a 100-minute nap; considered not medically necessary due to insufficient evidence

MSLTMultiple Sleep Latency Test: daytime study to confirm narcolepsy and evaluate hypersomnolence

MWTMaintenance of Wakefulness Test: assesses ability to remain awake and response to treatment

Archived previous policy version CS098ID.A.